JP2023515821A5 - - Google Patents
Info
- Publication number
- JP2023515821A5 JP2023515821A5 JP2022551247A JP2022551247A JP2023515821A5 JP 2023515821 A5 JP2023515821 A5 JP 2023515821A5 JP 2022551247 A JP2022551247 A JP 2022551247A JP 2022551247 A JP2022551247 A JP 2022551247A JP 2023515821 A5 JP2023515821 A5 JP 2023515821A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antigen
- antibody
- axl
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982852P | 2020-02-28 | 2020-02-28 | |
| US62/982,852 | 2020-02-28 | ||
| PCT/IB2021/051636 WO2021171257A1 (en) | 2020-02-28 | 2021-02-26 | Anti-axl antibodies and compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023515821A JP2023515821A (ja) | 2023-04-14 |
| JP2023515821A5 true JP2023515821A5 (https=) | 2024-03-01 |
| JP7748377B2 JP7748377B2 (ja) | 2025-10-02 |
Family
ID=75426640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551247A Active JP7748377B2 (ja) | 2020-02-28 | 2021-02-26 | 抗ａｘｌ抗体及び組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11807688B2 (https=) |
| EP (1) | EP4110824A1 (https=) |
| JP (1) | JP7748377B2 (https=) |
| KR (1) | KR20220148237A (https=) |
| CN (1) | CN115210263A (https=) |
| AR (1) | AR121441A1 (https=) |
| AU (1) | AU2021225490B2 (https=) |
| BR (1) | BR112022015977A2 (https=) |
| CA (1) | CA3170975A1 (https=) |
| CL (1) | CL2022002259A1 (https=) |
| CO (1) | CO2022012159A2 (https=) |
| IL (1) | IL295596A (https=) |
| MX (1) | MX2022010670A (https=) |
| MY (1) | MY209381A (https=) |
| PE (1) | PE20221783A1 (https=) |
| PH (1) | PH12022552041A1 (https=) |
| WO (1) | WO2021171257A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026001894A1 (zh) * | 2024-06-24 | 2026-01-02 | 上海医药集团生物治疗技术有限公司 | 靶向axl的嵌合抗原受体及其用途 |
| CN121851176A (zh) * | 2024-11-28 | 2026-04-14 | 北京大学深圳研究生院 | 抗人axl抗体、基因及其应用 |
| CN119912586B (zh) * | 2024-12-31 | 2025-09-30 | 四川省肿瘤医院 | 基于受体酪氨酸激酶家族axl改造的嵌合抗原受体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| AU2008321835B2 (en) | 2007-11-15 | 2014-11-20 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody capable of binding to anexelekto, and use thereof |
| CA2759836A1 (en) * | 2009-05-11 | 2010-11-18 | U3 Pharma Gmbh | Humanized axl antibodies |
| RU2577986C2 (ru) | 2010-06-18 | 2016-03-20 | Дженентек, Инк. | Антитела против axl и способы их применения |
| MA38165A1 (fr) * | 2012-11-08 | 2018-07-31 | Hoffmann La Roche | Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3 |
| GB201410826D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| AU2015366213B2 (en) | 2014-12-18 | 2021-10-07 | Bergenbio Asa | Anti-Axl antagonistic antibodies |
| PL3319993T3 (pl) * | 2015-07-10 | 2020-07-27 | Genmab A/S | Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka |
| ES2924402T3 (es) * | 2015-10-02 | 2022-10-06 | Symphogen As | Anticuerpos anti-PD-1 y composiciones |
| PH12018502112B1 (en) * | 2016-04-12 | 2024-03-27 | Servier Lab | Anti-tim-3 antibodies and compositions |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| CA3095986A1 (en) * | 2018-04-10 | 2019-10-17 | Genmab A/S | Axl-specific antibodies for cancer treatment |
-
2021
- 2021-02-26 US US17/186,465 patent/US11807688B2/en active Active
- 2021-02-26 MX MX2022010670A patent/MX2022010670A/es unknown
- 2021-02-26 IL IL295596A patent/IL295596A/en unknown
- 2021-02-26 AU AU2021225490A patent/AU2021225490B2/en active Active
- 2021-02-26 CA CA3170975A patent/CA3170975A1/en active Pending
- 2021-02-26 BR BR112022015977A patent/BR112022015977A2/pt unknown
- 2021-02-26 MY MYPI2022004441A patent/MY209381A/en unknown
- 2021-02-26 WO PCT/IB2021/051636 patent/WO2021171257A1/en not_active Ceased
- 2021-02-26 CN CN202180017213.3A patent/CN115210263A/zh active Pending
- 2021-02-26 JP JP2022551247A patent/JP7748377B2/ja active Active
- 2021-02-26 EP EP21717200.6A patent/EP4110824A1/en active Pending
- 2021-02-26 PH PH1/2022/552041A patent/PH12022552041A1/en unknown
- 2021-02-26 PE PE2022001857A patent/PE20221783A1/es unknown
- 2021-02-26 KR KR1020227033462A patent/KR20220148237A/ko active Pending
- 2021-02-26 AR ARP210100499A patent/AR121441A1/es unknown
-
2022
- 2022-08-18 CL CL2022002259A patent/CL2022002259A1/es unknown
- 2022-08-25 CO CONC2022/0012159A patent/CO2022012159A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023515821A5 (https=) | ||
| Yarden et al. | The ERBB network: at last, cancer therapy meets systems biology | |
| CN110872577B (zh) | 修饰的免疫细胞及其应用 | |
| Kraus et al. | Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. | |
| ES2230537T3 (es) | Una tirosina quinasa de tipo receptor (quinasa de tipo eph/elk hunaba-henki y uso de la misma. | |
| HRP20221041T1 (hr) | Anti-pd-1 antitijela i sastavi | |
| JP2022547081A5 (https=) | ||
| Chen et al. | A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy | |
| ES2784385T3 (es) | Composiciones direccionadas al dominio extracelular soluble de la cadherina-E y procedimientos relacionados para la terapia del cáncer | |
| BR112021005246A2 (pt) | agente terapêutico, e, método de tratamento para câncer | |
| JP2024527606A5 (https=) | ||
| ES3025738T9 (en) | Antibodies that bind egfr and cmet | |
| JP2021511811A5 (https=) | ||
| JP2023522630A5 (https=) | ||
| JP2017534259A5 (https=) | ||
| CA3089254A1 (en) | Bispecific antibody and uses thereof | |
| JP2022548764A5 (https=) | ||
| BR112021001509A2 (pt) | agente terapêutico para um tumor de cérebro metastásico | |
| US9650638B2 (en) | Aptamer for periostin and anti-cancer composition including same | |
| JP2022551662A (ja) | Ｂｃｍａを標的とする、ヒトサルの交差反応性を有するヒト化モノクローナル抗体 | |
| JP2008508858A5 (https=) | ||
| JP2015516370A (ja) | 癌の治療 | |
| JP2024520577A5 (https=) | ||
| ES2739925T3 (es) | Agente específico de RANKL para el tratamiento de una enfermedad metastásica | |
| JP2023525991A5 (https=) |